US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

50.10

+0.01000.02%

Post-market: 50.100.00000.00%17:48 EDT

Volume:300.31K

Turnover:15.01M

Market Cap:15.32B

PE:22.47

High:50.39

Open:49.79

Low:49.70

Close:50.09

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:0.95

T/O Rate:0.10%

Dividend:2.10

Dividend Rate:4.19%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.65

PE(LYR):20.32

Loading ...

Overview Company News Filings

Zevra Therapeutics (ZVRA) Is Down 25.4% After EMA Rejects Arimoclomol MAA In NPC Re-Examination Bid

Simply Wall St.

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Roche announces EMA’s CHMP recommended approval of Susvimo

Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55

MT Newswires Live

Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

Emera (EMA) Gets a Hold from Desjardins

Analysts Offer Insights on Utilities Companies: Emera (EMA) and Brookfield Renewable (BEPC)

J.P. Morgan Sticks to Its Hold Rating for Emera (EMA)

Emera price target raised to C$77 from C$74 at CIBC

GSK announces EMA accepted submission to update Bexsero label

BMO Capital Sticks to Its Buy Rating for Emera (EMA)

CIBC Keeps Their Hold Rating on Emera (EMA)

Emera price target raised to C$77 from C$74 at CIBC

Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases

Press Release: Correcting and Replacing Emera Declares Quarterly Dividends

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Celltrion Terminates, Withdraws EMA Trial Application for CT-P51 Biosimilar

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/EMA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":50.1,"timestamp":1788292800000,"preClose":50.09,"halted":0,"volume":300312,"hourTrading":{"tag":"盘后","latestPrice":50.1,"preClose":50.1,"latestTime":"17:48 EDT","volume":91891,"amount":4605882.82488,"timestamp":1788299311366,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.000199640646835656,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"09-01 16:00:00 EDT","open":49.785,"high":50.39,"low":49.7,"amount":15012134.39952,"amplitude":0.013775,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788336000000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":50.09,"dividendRate":0.042091,"preHourTrading":{"tag":"盘前","latestPrice":50.09,"preClose":50.09,"latestTime":"09:01 EDT","volume":3576,"amount":179121.19632000002,"timestamp":1788267706219,"change":0,"changeRate":0,"amplitude":0.001597},"postHourTrading":{"tag":"盘后","latestPrice":50.1,"preClose":50.1,"latestTime":"17:48 EDT","volume":91891,"amount":4605882.82488,"timestamp":1788299311366,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.945549,"impliedVol":0.282,"impliedVolPercentile":0.8566},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":0.945549,"shares":305783111,"dividePrice":2.098875,"high":50.39,"amplitude":0.013775,"preClose":50.09,"low":49.7,"week52Low":45.77,"pbRate":"1.65","psRate":"2.39","week52High":55.49,"institutionHeld":0,"latestPrice":50.1,"eps":2.229761,"divideRate":0.041894,"volume":300312,"delay":0,"ttmEps":2.229761,"open":49.785,"prevYearClose":49.24,"prevWeekClose":49.9,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":50.47,"twentyDayClose":52.37,"sixtyDayClose":51.76,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-08-31","current":22.468776,"percent":0.629393,"low":16.637027,"twenty":17.647618,"median":20.228077,"eighty":21.044729,"high":22.07626,"avg":19.80828,"sd":1.492623,"marketCap":15382546443.4},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-08-31","current":20.5056,"twenty":17.647618,"median":20.228077,"eighty":21.044729,"marketCap":15382546443.4}],"updateTime":1788335165012},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654098656","title":"Zevra Therapeutics (ZVRA) Is Down 25.4% After EMA Rejects Arimoclomol MAA In NPC Re-Examination Bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2654098656","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654098656?lang=en_us&edition=fundamental","pubTime":"2026-07-27 08:24","pubTimestamp":1785111889,"startTime":"0","endTime":"0","summary":"In July 2026, Zevra Therapeutics reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol in Niemann-Pick disease type C, prompting the company to seek a formal re-examination while maintaining patient access through its global Expanded Access Program.\nThe updated international Consensus Clinical Management Guidelines for Niemann-Pick disease type C highlight arimoclomol...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/zevra-therapeutics-zvra-is-down-254-after-ema-rejects-arimoc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/zevra-therapeutics-zvra-is-down-254-after-ema-rejects-arimoc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZVRA","BK4007","BK4588","BK4081","SPRE","BK4215","EMA","MAA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654206030","title":"Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654206030","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654206030?lang=en_us&edition=fundamental","pubTime":"2026-07-27 07:30","pubTimestamp":1785108600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, July  26, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/26/3333236/0/en/Ascentage-Pharma-Chairman-and-CEO-Dr-Dajun-Yang-Named-to-The-Medicine-Maker-Power-List-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4084","BK4234","AAPG","EMA","BK4081","PW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653847087","title":"Roche announces EMA’s CHMP recommended approval of Susvimo","url":"https://stock-news.laohu8.com/highlight/detail?id=2653847087","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653847087?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:50","pubTimestamp":1784897430,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-announces-emas-chmp-recommended-approval-of-susvimo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-announces-emas-chmp-recommended-approval-of-susvimo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANC","BK4087","CHMP","BK4007","BK4081","RHHBY","HRTS","EPV","EMA","03165"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653785088","title":"Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55","url":"https://stock-news.laohu8.com/highlight/detail?id=2653785088","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653785088?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:28","pubTimestamp":1784885304,"startTime":"0","endTime":"0","summary":"Celltrion  has submitted a marketing authorization application to the European Medicines Agency and European Commission for CT-P55, a biosimilar to Cosentyx , according to a bourse filing on Friday.The company seeks approval for adult plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis, plus pediatric plaque psoriasis and juvenile idiopathic arthritis subtypes.The application is based on a Phase 1 trial in 172 healthy subjects that demonstrated pharmacokinetic equivalence to Cosentyx, with similar safety profiles and low immunogenicity across both groups.The company cautions that submitting an application does not guarantee final approval, and regulatory reviews may yield unexpected outcomes or lead to changes in commercialization plans.This MAA follows prior EMA submissions and approvals for the drug's clinical trial applications between 2023 and 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653088115","title":"Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653088115","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653088115?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:23","pubTimestamp":1784885030,"startTime":"0","endTime":"0","summary":"Celltrion  has submitted applications for its subcutaneous rheumatoid arthritis drug CT-P13 SC  to both the U.S. FDA  and the European Medicines Agency .The company seeks to demonstrate superiority over placebo at 12 weeks in a 296-patient, 52-week global Phase 3 trial, according to a bourse filing on Friday.The subcutaneous formulation, already approved for ulcerative colitis and Crohn's disease in multiple regions, aims to expand its indications and improve patient convenience through a broader treatment population.The company cautions that historically only about 10% of clinical trial drugs ultimately receive marketing approval, and results may fall short of expectations.While both filings share the same clinical design and commercial rationale, the EMA submission explicitly addresses the EU's revised Clinical Trials Regulation requiring separate Part 1  and Part 2  approvals.Both submissions support commercial differentiation through patient diversity, though investors are urged to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA","BK7095","IND","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653556757","title":"BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1","url":"https://stock-news.laohu8.com/highlight/detail?id=2653556757","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653556757?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:30","pubTimestamp":1784719800,"startTime":"0","endTime":"0","summary":"- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/22/3331254/0/en/BridgeBio-Announces-FDA-Acceptance-of-NDA-for-Encaleret-for-ADH1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","LABU","MAA","BK4215","BK4588","SPRE","BK4585","BK4081","ENDO","PTH","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653675789","title":"Emera (EMA) Gets a Hold from Desjardins","url":"https://stock-news.laohu8.com/highlight/detail?id=2653675789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653675789?lang=en_us&edition=fundamental","pubTime":"2026-07-22 06:19","pubTimestamp":1784672383,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brent Stadler from Desjardins maintained a Hold rating on Emera, with a price target of C$74.00. The company’s shar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/emera-ema-gets-a-hold-from-desjardins-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/emera-ema-gets-a-hold-from-desjardins-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653778988","title":"Analysts Offer Insights on Utilities Companies: Emera (EMA) and Brookfield Renewable (BEPC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653778988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653778988?lang=en_us&edition=fundamental","pubTime":"2026-07-22 06:10","pubTimestamp":1784671851,"startTime":"0","endTime":"0","summary":"Companies in the Utilities sector have received a lot of coverage today as analysts weigh in on Emera (EMA) and Brookfield Renewable (BEPC). Emera ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-utilities-companies-emera-ema-and-brookfield-renewable-bepc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-utilities-companies-emera-ema-and-brookfield-renewable-bepc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","IE00BMG7P702.HKD","IE00BMG7P587.USD","IE00BMG7P694.USD","BK4081","BK4133","IE00BMG7P926.USD","BEPC","IE00BMG7P819.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653378552","title":"J.P. Morgan Sticks to Its Hold Rating for Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653378552","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653378552?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:47","pubTimestamp":1784666833,"startTime":"0","endTime":"0","summary":"In a report released today, Eli Jossen from J.P. Morgan maintained a Hold rating on Emera, with a price target of C$79.00. According to TipRanks, J...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-hold-rating-for-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-hold-rating-for-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653210199","title":"Emera price target raised to C$77 from C$74 at CIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2653210199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653210199?lang=en_us&edition=fundamental","pubTime":"2026-07-21 01:20","pubTimestamp":1784568030,"startTime":"0","endTime":"0","summary":"CIBC raised the firm’s price target on Emera (EMA) to C$77 from C$74 and keeps a Neutral rating on the shares. Published first on TheFly – the ulti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c77-from-c74-at-cibc-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c77-from-c74-at-cibc-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297452","title":"GSK announces EMA accepted submission to update Bexsero label","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297452","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297452?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:40","pubTimestamp":1784544023,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced the European Medicines Agency, EMA, has accepted a submission to update the label for Bexsero to include a single dose booster ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-announces-ema-accepted-submission-to-update-bexsero-label-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-announces-ema-accepted-submission-to-update-bexsero-label-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1829250122.USD","EPV","GSKH","BK4588","BK4081","BK4585","GSK","GSK.UK","BK4532","BK4007","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652252371","title":"BMO Capital Sticks to Its Buy Rating for Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652252371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652252371?lang=en_us&edition=fundamental","pubTime":"2026-07-19 23:55","pubTimestamp":1784476520,"startTime":"0","endTime":"0","summary":"In a report released on July 17, Benjamin Pham from BMO Capital reiterated a Buy rating on Emera, with a price target of C$76.00. The company’s sha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bmo-capital-sticks-to-its-buy-rating-for-emera-ema-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bmo-capital-sticks-to-its-buy-rating-for-emera-ema-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMO","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652394282","title":"CIBC Keeps Their Hold Rating on Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652394282","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652394282?lang=en_us&edition=fundamental","pubTime":"2026-07-18 00:55","pubTimestamp":1784307317,"startTime":"0","endTime":"0","summary":"In a report released today, Mark Jarvi from CIBC maintained a Hold rating on Emera, with a price target of C$77.00. Jarvi covers the Utilities sect...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cibc-keeps-their-hold-rating-on-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cibc-keeps-their-hold-rating-on-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652284238","title":"Emera price target raised to C$77 from C$74 at CIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2652284238","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652284238?lang=en_us&edition=fundamental","pubTime":"2026-07-18 00:10","pubTimestamp":1784304633,"startTime":"0","endTime":"0","summary":"CIBC analyst Mark Jarvi raised the firm’s price target on Emera (EMA) to C$77 from C$74 and keeps a Neutral rating on the shares. In a sector previ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c77-from-c74-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c77-from-c74-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652422420","title":"Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2652422420","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652422420?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:35","pubTimestamp":1784234123,"startTime":"0","endTime":"0","summary":"Vanda Pharmaceuticals (VNDA) announced that the Committee for Orphan Medicinal Products at the European Medicines Agency has adopted a positive opi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vanda-announces-ema-positive-opinion-for-orphan-drug-designation-of-imsidolimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vanda-announces-ema-positive-opinion-for-orphan-drug-designation-of-imsidolimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","VNDA","BK4081","EPV","EMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449622","title":"Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449622","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449622?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201400,"startTime":"0","endTime":"0","summary":"STAFFORD, Texas, July  16, 2026  (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \"Company\"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FL","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/16/3328362/0/en/Greenwich-LifeSciences-Announces-European-Approval-for-Combining-Both-HLA-Populations-in-FLAMINGO-01.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081","DTH","BK4139","IDNA","GLSI","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651498775","title":"Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2651498775","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651498775?lang=en_us&edition=fundamental","pubTime":"2026-07-16 02:15","pubTimestamp":1784139300,"startTime":"0","endTime":"0","summary":"CHICAGO, July  15, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (\"Cosmos Health\" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/15/3328051/0/en/Cosmos-Health-Share-Buyback-Surpasses-4-5-Million-Shares-Continues-Open-Market-Repurchases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4175","EMA","BK4081","COSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651645435","title":"Press Release: Correcting and Replacing Emera Declares Quarterly Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2651645435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651645435?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:16","pubTimestamp":1784110560,"startTime":"0","endTime":"0","summary":"HALIFAX, Nova Scotia----July 15, 2026--Series J First Preferred Share quarterly dividend in release dated July 13, 2026, should read: $0.39660 .The updated release readsEMERA DECLARES QUARTERLY DIVIDENDSOn July 13, 2026, the Board of Directors of Emera Inc.  declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after August 17, 2026 to the applicable shareholders of record at the close of business on August 3, 2026, as follows:1.  $0.7325 per common share;","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651057651","title":"Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2651057651","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651057651?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:45","pubTimestamp":1784029500,"startTime":"0","endTime":"0","summary":"Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026 Preclinical data for sutacimig in Factor VII ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326747/0/en/Hemab-Therapeutics-Presents-Clinical-and-Preclinical-Data-from-Sutacimig-in-Glanzmann-Thrombasthenia-and-Factor-VII-Deficiency-at-the-ISTH-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4119","BK4588","BK4139","BK4081","LENZ","GT","EMA","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651175771","title":"Celltrion Terminates, Withdraws EMA Trial Application for CT-P51 Biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2651175771","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651175771?lang=en_us&edition=fundamental","pubTime":"2026-07-14 16:56","pubTimestamp":1784019385,"startTime":"0","endTime":"0","summary":"Celltrion  voluntarily terminated and withdrew its European Phase 3 clinical trial application for CT-P51, its biosimilar to cancer drug Keytruda, from the European Medicines Agency, according to a regulatory filing on Tuesday.The South Korean biopharmaceutical company said the withdrawal follows changes in the global regulatory environment for biosimilar clinical trials.The company has updated its clinical and regulatory strategy for Phase 3 trials in previously untreated metastatic non-squamous non-small cell lung cancer, reducing the number of patients recruited for the trial.The company will continue the Phase 3 study in participating countries outside the European Union, comparing the efficacy and safety of CT-P51 against the reference drug Keytruda.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPV","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}